Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director · Chief Executive Officer | September 11, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 157,266 |
Reported balance
After 2026-09-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-11 · Grant · Acquired 6,275 · Balance 157,266 F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. F2: Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 153,880 |
Reported balance
After 2026-09-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-11 · Tax withholding · Disposed 3,386 · Balance 153,880 F3: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. |
| Common StockSEC Table I · non-derivative | Direct | 155,722 |
Reported balance
After 2026-09-11 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-11 · Grant · Acquired 1,842 · Balance 155,722 F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 154,728 |
Reported balance
After 2026-09-11 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-09-11 · Tax withholding · Disposed 994 · Balance 154,728 F3: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
F2: Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
F3: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 07, 2019 Filed Feb 8, 2019 22:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 66,673 | $0.00 Strike: $81.05 | $0.00 |
DisclosureSEC source: 0001209191-19-008630 · doc4.xml · derivative · entry 2 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,673 Underlying: Common Stock · 66,673 shares Expires 2029-02-07 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 22:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 762 | $83.56 | $63,672.64 |
DisclosureSEC source: 0001209191-19-008630 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,833 F1 · kind: Sale of 762 shares of common stock issued upon vesting of 1,900 restricted stock units on February 6, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,138) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.79 to $85.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2019 Filed Feb 6, 2019 23:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 669 | $88.14 | $58,962.52 |
DisclosureSEC source: 0001209191-19-007849 · doc4.xml · nonDerivative · entry 4 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,695 F7 · kind: Sale of 669 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,256) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.40 to $88.67. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2019 Filed Feb 6, 2019 23:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,300 | $88.14 | $114,575.89 |
DisclosureSEC source: 0001209191-19-007849 · doc4.xml · nonDerivative · entry 3 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,439 F5 · kind: Sale of 1,300 shares of common stock issued upon vesting of 3,750 restricted stock units on February 5, 2019 to cover payroll and withholding taxes, with the balance of the shares (2,450) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.40 to $88.67. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2019 Filed Feb 6, 2019 23:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 465 | $88.05 | $40,943.20 |
DisclosureSEC source: 0001209191-19-007849 · doc4.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,989 F3 · kind: Sale of 465 shares of common stock issued upon vesting of 1,337 restricted stock units on February 5, 2019 to cover payroll and withholding taxes, with the balance of the shares (872) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.35 to $88.46. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 23:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,375 | $88.14 | $121,186.31 |
DisclosureSEC source: 0001209191-19-007849 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,117 F1 · kind: Sale of 1,375 shares of common stock issued upon vesting of 2,750 restricted stock units on February 4, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,375) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.76 to $88.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 20:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 28,266 | $8.66 Strike: $8.66 | $244,783.56 |
DisclosureSEC source: 0001209191-18-045265 · doc4.xml · derivative · entry 3 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,266 Underlying: Common Stock · 28,266 shares Expires 2022-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option granted January 12, 2012 and vested monthly over four years. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 20:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 28,266 | $115.00 | $3,250,590.00 |
DisclosureSEC source: 0001209191-18-045265 · doc4.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,742 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 20:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 28,266 | $8.66 | $244,783.56 |
DisclosureSEC source: 0001209191-18-045265 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 23,650 | $8.65 Strike: $8.65 | $204,572.50 |
DisclosureSEC source: 0001209191-18-017709 · doc4.xml · derivative · entry 3 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,650 shares Expires 2023-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option granted January 10, 2013 and vested monthly over four years. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 23,650 | $90.00 | $2,128,500.00 |
DisclosureSEC source: 0001209191-18-017709 · doc4.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,742 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 23,650 | $8.65 | $204,572.50 |
DisclosureSEC source: 0001209191-18-017709 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 22:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 658 | $82.48 | $54,271.84 |
DisclosureSEC source: 0001209191-18-008204 · doc4.xml · nonDerivative · entry 3 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,446 F5 · kind: Payment of tax liability by withholding 658 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (1,242) maintained by the Reporting Person. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 22:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008204 · doc4.xml · derivative · entry 7 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F8 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. F8 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 22:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008204 · doc4.xml · derivative · entry 6 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2021-03-15 F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F9 · derivative.exercise_date: A portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of specified revenue milestones within a specified time period. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 22:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 5,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008204 · doc4.xml · derivative · entry 5 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,350 Underlying: Common Stock · 5,350 shares Expires not disclosed F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F8 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. F8 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 22:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 30,400 | $0.00 Strike: $81.49 | $0.00 |
DisclosureSEC source: 0001209191-18-008204 · doc4.xml · derivative · entry 4 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,400 Underlying: Common Stock · 30,400 shares Expires 2028-02-05 F6 · derivative.exercise_date: Represents option of which 1/48th March 5, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 22:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 671 | $83.19 | $55,818.61 |
DisclosureSEC source: 0001209191-18-008204 · doc4.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,204 F3 · kind: Sale of 671 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,254) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 22:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,375 | $82.98 | $114,095.30 |
DisclosureSEC source: 0001209191-18-008204 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,950 F1 · kind: Sale of 1,375 shares of common stock issued upon vesting of 2,750 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,375) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 21:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,625 | $79.05 | $128,459.50 |
DisclosureSEC source: 0001209191-18-004237 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,871 F1 · kind: Sale of 1,625 shares of common stock issued upon vesting of 3,250 restricted stock units on January 16, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,625) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $76.17 to $81.83. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionIncentive Stock Option · Derivative | 13,468 | $8.66 Strike: $8.66 | $116,632.88 |
DisclosureSEC source: 0001209191-17-059430 · doc4.xml · derivative · entry 6 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,468 shares Expires 2022-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted January 12, 2012 and vested monthly over four years. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionIncentive Stock Option · Derivative | 11,350 | $8.65 Strike: $8.65 | $98,177.50 |
DisclosureSEC source: 0001209191-17-059430 · doc4.xml · derivative · entry 5 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,350 shares Expires 2023-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option granted January 10, 2013 and vested monthly over four years. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 13,468 | $71.05 | $956,901.40 |
DisclosureSEC source: 0001209191-17-059430 · doc4.xml · nonDerivative · entry 4 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,246 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 13,468 | $8.66 | $116,632.88 |
DisclosureSEC source: 0001209191-17-059430 · doc4.xml · nonDerivative · entry 3 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 11,350 | $71.05 | $806,417.50 |
DisclosureSEC source: 0001209191-17-059430 · doc4.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,246 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 11,350 | $8.65 | $98,177.50 |
DisclosureSEC source: 0001209191-17-059430 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 18:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionStock Option · Derivative | 4,607 | $8.65 Strike: $8.65 | $39,850.55 |
DisclosureSEC source: 0001209191-17-052021 · doc4.xml · derivative · entry 3 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,390 Underlying: Common Stock · 4,607 shares Expires 2023-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option granted January 10, 2013 and vested monthly over four years. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 18:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 4,607 | $60.00 | $276,420.00 |
DisclosureSEC source: 0001209191-17-052021 · doc4.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,246 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 18:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 4,607 | $8.65 | $39,850.55 |
DisclosureSEC source: 0001209191-17-052021 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2017 Filed Oct 3, 2017 23:13 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionStock Option · Derivative | 20,393 | $8.65 Strike: $8.65 | $176,399.45 |
DisclosureSEC source: 0001209191-17-055452 · doc4.xml · derivative · entry 3 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 20,393 shares Expires 2023-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option granted January 10, 2013 and vested monthly over four years. Read SEC document |
| September 06, 2017 Filed Oct 3, 2017 23:13 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 20,393 | $60.00 | $1,223,580.00 |
DisclosureSEC source: 0001209191-17-055452 · doc4.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,246 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| September 06, 2017 Filed Oct 3, 2017 23:13 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 20,393 | $8.65 | $176,399.45 |
DisclosureSEC source: 0001209191-17-055452 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2017 Filed May 3, 2017 22:41 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,000 | $2.59 Strike: $2.59 | $38,850.00 |
DisclosureSEC source: 0001209191-17-029797 · doc4.xml · derivative · entry 3 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2017-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted May 11, 2010 and vests in 36 equal monthly installments beginning June 11, 2010. Read SEC document |
| May 01, 2017 Filed May 3, 2017 22:41 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 15,000 | $54.00 | $810,000.00 |
DisclosureSEC source: 0001209191-17-029797 · doc4.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,246 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $53.65 to $54.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 01, 2017 Filed May 3, 2017 22:41 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,000 | $2.59 | $38,850.00 |
DisclosureSEC source: 0001209191-17-029797 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 20:53 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 204 | $51.23 | $10,450.92 |
DisclosureSEC source: 0001209191-17-026879 · doc4.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,246 F1 · kind: Sale of 13,065 shares of common stock issued upon vesting of 25,000 performance restricted stock units on April 11, 2017 to cover withholding taxes, with the balance of the shares (11,935) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $51.19 to $51.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 20:53 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 12,861 | $50.41 | $648,323.01 |
DisclosureSEC source: 0001209191-17-026879 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,450 F1 · kind: Sale of 13,065 shares of common stock issued upon vesting of 25,000 performance restricted stock units on April 11, 2017 to cover withholding taxes, with the balance of the shares (11,935) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $50.20 to $50.73. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Option · Derivative | 7,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008915 · doc4.xml · derivative · entry 3 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,600 Underlying: Common Stock · 7,600 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 60,000 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001209191-17-008915 · doc4.xml · derivative · entry 2 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-02-06 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2017 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 727 | $43.15 | $31,370.05 |
DisclosureSEC source: 0001209191-17-008915 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,311 F1 · kind: Sale of 727 shares of common stock issued upon vesting of 1925 restricted stock units to cover withholding taxes with the balance of the shares (1198) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.69 to $43.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 00:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,375 | $42.57 | $58,533.75 |
DisclosureSEC source: 0001209191-17-008135 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,113 F1 · kind: Sale of 1,375 shares of common stock issued upon vesting of 2,750 restricted stock units on February 3, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,375) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $41.80 to $43.29. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,625 | $40.65 | $66,056.25 |
DisclosureSEC source: 0001209191-17-004304 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,738 F1 · kind: Sale of 1,625 shares of common stock issued upon vesting of 3,250 restricted stock units on January 17, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,625) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $39.98 to $41.76. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 10, 2017 Filed Jan 13, 2017 00:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,250 | $43.37 | $54,212.50 |
DisclosureSEC source: 0001209191-17-003585 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,113 F1 · kind: Sale of 1,250 shares of common stock issued upon vesting of 2,500 restricted stock units on January 10, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,250) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.60 to $45.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.